Ansell (ASX:ANN) Posts Strong Full Year Results, Is The Upside Already Priced In?
Ansell (ASX:ANN) is in focus after reporting full year 2026 sales of US$2,140.2 million and net income of US$208.6 million, alongside a higher earnings per share figure and a fresh dividend declaration.
The earnings release and dividend news follow a period of strong recent trading, with Ansell’s 90-day share price return of 47.18% and 1-year total shareholder return of 22.15% signalling building momentum at the current A$40.99 share price.
Compare Ansell's move with a hand picked 13 high quality undervalued stocks that currently pair stronger balance sheets and cash flows with share prices that some investors may see as lagging the recent fundamentals.
Bulls point to Ansell's rising earnings, buyback and dividend. Bears question how much of that strength is already reflected after a 47.18% 90 day jump. The numbers now set the stage for a valuation check.
Most Popular Narrative: 20.2% Overvalued
On the most followed narrative, Ansell’s fair value sits at A$34.10 compared with the current A$40.99 share price. This puts the narrative view on the cautious side.
Margin improvement and financial strength post-pandemic: Following pandemic-era supply disruptions and demand volatility, Ansell has undertaken a structural reset of its operations through its Accelerated Productivity Investment Program (APIP), launched in July 2023 to streamline manufacturing, improve supply-chain efficiency, and unify enterprise systems. The program has already delivered approximately US$47 million (on track to save $50 million in FY26) in annualised savings and completed key phases of manufacturing consolidation, including the relocation of certain production from China to Sri Lanka and warehouse upgrades across the US, UK, and Mexico. This is reflected in a reversal of its share price trajectory, beginning in 2023, when the program was launched. APIP has supported gross profit margin uplift from 34.1% in FY22 to 41.1% in FY25.
Want to see how this margin story translates into that A$34.10 fair value for Ansell? The narrative leans heavily on earnings quality, productivity gains and future profitability assumptions that are not obvious from headline numbers alone.
Result: Fair Value of A$34.10 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to watch for rising competition from lower cost PPE producers, as well as any setback in delivering APIP and KBU integration benefits.
Find out about the key risks to this Ansell narrative.
Another View on Ansell’s Valuation
The most popular narrative pegs Ansell at 20.2% above its A$34.10 fair value. Yet on earnings multiples, the picture looks different. Ansell trades on a P/E of 19.6x versus a fair ratio of 26x and a global medical equipment average of 24.5x. This suggests less valuation pressure than the narrative implies. So which signal should carry more weight for you right now?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Does the mixed sentiment on Ansell leave you unsure which signal to trust? Act while the information is fresh and test the findings against the 4 key rewards.
Looking for more investment ideas beyond Ansell?
If Ansell has sharpened your focus on opportunities, do not stop here. Use fresh data driven shortlists to pressure test your next moves and avoid blind spots.
- Spot potential mispricings early by reviewing the 13 high quality undervalued stocks that some investors may see as out of sync with current fundamentals.
- Strengthen your income backbone with the 8 dividend fortresses that focus on higher yields combined with stability.
- Protect your downside first by scanning the 12 resilient stocks with low risk scores that emphasise resilient balance sheets and lower overall risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com